Cephalon Inc., the maker of the sleep disorder drug Provigil, reported a profit in the fourth-quarter and said sales declined.

Profit was $44.2 million, or 56 cents a share, compared with a net loss of $4.91 million, or 8 cents a year earlier, the drugmaker, based in Frazer, Penn., said this week in a news release. Sales fell to $449.9 million from $484.7 million.

Cephalon produces several products in Salt Lake City, including Actiq.